{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T20:34:20Z","timestamp":1784752460603,"version":"3.55.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T00:00:00Z","timestamp":1542067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s00296-018-4195-x","type":"journal-article","created":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T07:02:21Z","timestamp":1542092541000},"page":"121-130","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Treatment patterns, unmet need, and impact on patient-reported outcomes of psoriatic arthritis in the United States and Europe"],"prefix":"10.1007","volume":"39","author":[{"given":"Alice","family":"Gottlieb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Gratacos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ara","family":"Dikranian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"van Tubergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Fallon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birol","family":"Emir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laraine","family":"Aikman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,13]]},"reference":[{"key":"4195_CR1","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","volume":"68","author":"LC Coates","year":"2016","unstructured":"Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Laura Acosta-Felquer M, Armstrong AW, Bautista-Molano W, Boehncke WH, Campbell W, Cauli A, Espinoza LR, FitzGerald O, Gladman DD, Gottlieb A, Helliwell PS, Husni ME, Love TJ, Lubrano E, McHugh N, Nash P, Ogdie A, Orbai AM, Parkinson A, O\u2019Sullivan D, Rosen CF, Schwartzman S, Siegel EL, Toloza S, Tuong W, Ritchlin CT (2016) Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol 68:1060\u20131071","journal-title":"Arthritis Rheumatol"},{"key":"4195_CR2","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3899\/jrheum.170150","volume":"44","author":"A Ogdie","year":"2017","unstructured":"Ogdie A, de Wit M, Callis Duffin K, Campbell W, Chau J, Coates LC, Eder L, Elmamoun M, Fitzgerald O, Gladman DD, Goel N, James J, Kalyoncu U, Latella J, Lindsay C, Mease PJ, O\u2019Sullivan D, Steinkoenig I, Strand V, Tillett W, Orbai AM (2017) Defining outcome measures for psoriatic arthritis: a report from the GRAPPA-OMERACT working group. J Rheumatol 44:697\u2013700","journal-title":"J Rheumatol"},{"key":"4195_CR3","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1136\/annrheumdis-2016-210242","volume":"76","author":"AM Orbai","year":"2017","unstructured":"Orbai AM, de Wit M, Mease P, Shea JA, Gossec L, Leung YY, Tillett W, Elmamoun M, Callis Duffin K, Campbell W, Christensen R, Coates L, Dures E, Eder L, Fitzgerald O, Gladman D, Goel N, Grieb SD, Hewlett S, Hoejgaard P, Kalyoncu U, Lindsay C, McHugh N, Shea B, Steinkoenig I, Strand V, Ogdie A (2017) International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. Ann Rheum Dis 76:673\u2013680","journal-title":"Ann Rheum Dis"},{"key":"4195_CR4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s40744-016-0029-z","volume":"3","author":"A Kavanaugh","year":"2016","unstructured":"Kavanaugh A, Helliwell P, Ritchlin CT (2016) Psoriatic arthritis and burden of disease: patient perspectives from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey. Rheumatol Ther 3:91\u2013102","journal-title":"Rheumatol Ther"},{"key":"4195_CR5","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1111\/j.1365-2133.2008.09023.x","volume":"160","author":"K Reich","year":"2008","unstructured":"Reich K, Kruger K, Mossner R, Augustin M (2008) Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol 160:1040\u20131047","journal-title":"Br J Dermatol"},{"key":"4195_CR6","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.jaad.2013.07.023","volume":"69","author":"PJ Mease","year":"2013","unstructured":"Mease PJ, Gladman DD, Papp KA, Khraishi MM, Tha\u00e7i D, Behrens F, Northington R, Fuiman J, Bananis E, Boggs R, Alvarez D (2013) Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European\/North American dermatology clinics. J Am Acad Dermatol 69:729\u2013735","journal-title":"J Am Acad Dermatol"},{"key":"4195_CR7","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3899\/jrheum.080691","volume":"36","author":"FC Wilson","year":"2009","unstructured":"Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM (2009) Time trends in epidemiology and characteristics of psoriatic arthritis over 3 decades: a population-based study. J Rheumatol 36:361\u2013367","journal-title":"J Rheumatol"},{"key":"4195_CR8","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD (2017) Psoriatic arthritis. N Engl J Med 376:957\u2013970","journal-title":"N Engl J Med"},{"key":"4195_CR9","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.jaad.2013.12.018","volume":"70","author":"MG Lebwohl","year":"2014","unstructured":"Lebwohl MG, Bachelez H, Barker J, Girolomoni G, Kavanaugh A, Langley RG, Paul CF, Puig L, Reich K, van de Kerkhof PC (2014) Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol 70:871\u2013881","journal-title":"J Am Acad Dermatol"},{"key":"4195_CR10","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1136\/ard.2004.029207","volume":"64","author":"A Saraux","year":"2005","unstructured":"Saraux A, Guillemin F, Guggenbuhl P, Roux CH, Fardellone P, Le Bihan E, Cantagrel A, Chary-Valckenaere I, Euller-Ziegler L, Flipo RM, Juvin R, Behier JM, Fautrel B, Masson C, Coste J (2005) Prevalence of spondyloarthropathies in France: 2001. Ann Rheum Dis 64:1431\u20131435","journal-title":"Ann Rheum Dis"},{"key":"4195_CR11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/1529-0131(199801)41:1<58::AID-ART8>3.0.CO;2-G","volume":"41","author":"J Braun","year":"1998","unstructured":"Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, Sieper J (1998) Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 41:58\u201367","journal-title":"Arthritis Rheum"},{"key":"4195_CR12","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1093\/rheumatology\/kes324","volume":"52","author":"A Ogdie","year":"2013","unstructured":"Ogdie A, Langan S, Love T, Haynes K, Shin D, Seminara N, Mehta NN, Troxel A, Choi H, Gelfand JM (2013) Prevalence and treatment patterns of psoriatic arthritis in the UK. Rheumatology (Oxford England) 52:568\u2013575","journal-title":"Rheumatology (Oxford England)"},{"key":"4195_CR13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1080\/03009740600904243","volume":"36","author":"R Angelis De","year":"2007","unstructured":"De Angelis R, Salaffi F, Grassi W (2007) Prevalence of spondyloarthropathies in an Italian population sample: a regional community-based study. Scand J Rheumatol 36:14\u201321","journal-title":"Scand J Rheumatol"},{"key":"4195_CR14","doi-asserted-by":"crossref","first-page":"ii14","DOI":"10.1136\/ard.2004.032482","volume":"64","author":"DD Gladman","year":"2005","unstructured":"Gladman DD, Antoni C, Mease P, Clegg DO, Nash P (2005) Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64:ii14\u2013ii17","journal-title":"Ann Rheum Dis"},{"key":"4195_CR15","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s11926-015-0540-1","volume":"17","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, Gelfand JM (2015) Clinical risk factors for the development of psoriatic arthritis among patients with psoriasis: a review of available evidence. Curr Rheumatol Rep 17:64","journal-title":"Curr Rheumatol Rep"},{"key":"4195_CR16","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1002\/art.24608","volume":"61","author":"G Ibrahim","year":"2009","unstructured":"Ibrahim G, Waxman R, Helliwell PS (2009) The prevalence of psoriatic arthritis in people with psoriasis. Arthritis Rheum 61:1373\u20131378","journal-title":"Arthritis Rheum"},{"key":"4195_CR17","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/j.1468-3083.2009.03159.x","volume":"23","author":"MA Radtke","year":"2009","unstructured":"Radtke MA, Reich K, Blome C, Rustenbach S, Augustin M (2009) Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey. J Eur Acad Dermatol Venereol 23:683\u2013691","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4195_CR18","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s40257-013-0032-x","volume":"14","author":"WH Boehncke","year":"2013","unstructured":"Boehncke WH, Menter A (2013) Burden of disease: psoriasis and psoriatic arthritis. Am J Clin Dermatol 14:377\u2013388","journal-title":"Am J Clin Dermatol"},{"key":"4195_CR19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13075-017-1265-5","volume":"19","author":"M Bergman","year":"2017","unstructured":"Bergman M, Lundholm A (2017) Mitigation of disease- and treatment-related risks in patients with psoriatic arthritis. Arthritis Res Ther 19:63","journal-title":"Arthritis Res Ther"},{"key":"4195_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.reuma.2013.05.006","volume":"10","author":"J Gratac\u00f3s","year":"2014","unstructured":"Gratac\u00f3s J, Dauden E, G\u00f3mez-Reino J, Moreno JC, Casado M, Rodr\u00edguez-Valverde V (2014) Health-related quality of life in psoriatic arthritis patients in Spain. Reumatologia Clinica 10:25\u201331","journal-title":"Reumatologia Clinica"},{"key":"4195_CR21","doi-asserted-by":"publisher","first-page":"775.e771775.e77","DOI":"10.1016\/j.amjmed.2010.07.028","volume":"124","author":"NN Mehta","year":"2011","unstructured":"Mehta NN, Yu YD, Pinnelas R, Krishnamoorthy P, Shin DB, Troxel AB, Gelfand JM (2011) Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med 124:775.e771\u2013775.e776","journal-title":"Am J Med"},{"key":"4195_CR22","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1111\/bjd.12002","volume":"167","author":"T Xu","year":"2012","unstructured":"Xu T, Zhang YH (2012) Association of psoriasis with stroke and myocardial infarction: meta-analysis of cohort studies. Br J Dermatol 167:1345\u20131350","journal-title":"Br J Dermatol"},{"key":"4195_CR23","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1002\/art.24092","volume":"59","author":"JA Avi\u00f1a-Zubieta","year":"2008","unstructured":"Avi\u00f1a-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D (2008) Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheumatism 59:1690\u20131697","journal-title":"Arthritis Rheumatism"},{"key":"4195_CR24","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1136\/annrheumdis-2013-204223","volume":"73","author":"M Dougados","year":"2014","unstructured":"Dougados M, Soubrier M, Antunez A, Balint P, Balsa A, Buch MH, Casado G, Detert J, El-Zorkany B, Emery P, Hajjaj-Hassouni N, Harigai M, Luo SF, Kurucz R, Maciel G, Mola EM, Montecucco CM, McInnes I, Radner H, Smolen JS, Song YW, Vonkeman HE, Winthrop K, Kay J (2014) Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis 73:62\u201368","journal-title":"Ann Rheum Dis"},{"key":"4195_CR25","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1136\/ard.2010.143396","volume":"70","author":"J Lindhardsen","year":"2011","unstructured":"Lindhardsen J, Ahlehoff O, Gislason GH, Madsen OR, Olesen JB, Torp-Pedersen C, Hansen PR (2011) The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis 70:929\u2013934","journal-title":"Ann Rheum Dis"},{"key":"4195_CR26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/rheumatology\/kes305","volume":"52","author":"J Listing","year":"2013","unstructured":"Listing J, Gerhold K, Zink A (2013) The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology 52:53\u201361","journal-title":"Rheumatology"},{"key":"4195_CR27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/rheumatology\/kes189","volume":"52","author":"C Turesson","year":"2013","unstructured":"Turesson C, Matteson EL (2013) Malignancy as a comorbidity in rheumatic diseases. Rheumatology 52:5\u201314","journal-title":"Rheumatology"},{"key":"4195_CR28","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1093\/rheumatology\/ken090","volume":"47","author":"LS Tam","year":"2008","unstructured":"Tam LS, Tomlinson B, Chu TT, Li M, Leung YY, Kwok LW, Li TK, Yu T, Zhu YE, Wong KC, Kun EW, Li EK (2008) Cardiovascular risk profile of patients with psoriatic arthritis compared to controls\u2013the role of inflammation. Rheumatology 47:718\u2013723","journal-title":"Rheumatology"},{"key":"4195_CR29","first-page":"2167","volume":"33","author":"C Han","year":"2006","unstructured":"Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV (2006) Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 33:2167\u20132172","journal-title":"J Rheumatol"},{"key":"4195_CR30","doi-asserted-by":"publisher","first-page":"887","DOI":"10.3899\/jrheum.130797","volume":"41","author":"E McDonough","year":"2014","unstructured":"McDonough E, Ayearst R, Eder L, Chandran V, Rosen CF, Thavaneswaran A, Gladman DD (2014) Depression and anxiety in psoriatic disease: prevalence and associated factors. J Rheumatol 41:887\u2013896","journal-title":"J Rheumatol"},{"key":"4195_CR31","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1111\/bjd.14833","volume":"176","author":"RC Lamb","year":"2017","unstructured":"Lamb RC, Matcham F, Turner MA, Rayner L, Simpson A, Hotopf M, Barker JNWN, Jackson K, Smith CH (2017) Screening for anxiety and depression in people with psoriasis: a cross-sectional study in a tertiary referral setting. Br J Dermatol 176:1028\u20131034","journal-title":"Br J Dermatol"},{"key":"4195_CR32","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","volume":"58","author":"A Menter","year":"2008","unstructured":"Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA, Korman NJ, Beutner KR, Bhushan R (2008) Guidelines of care for the management of psoriasis and psoriatic arthritis: Sect. 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 58:826\u2013850","journal-title":"J Am Acad Dermatol"},{"key":"4195_CR33","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","volume":"75","author":"L Gossec","year":"2016","unstructured":"Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M, Emery P, Landew\u00e9 R, Oliver S, Aletaha D, Betteridge N, Braun J, Burmester G, Ca\u00f1ete JD, Damjanov N, Fitzgerald O, Haglund E, Helliwell P, Kvien TK, Lories R, Luger T, Maccarone M, Marzo-Ortega H, McGonagle D, McInnes IB, Olivieri I, Pavelka K, Schett G, Sieper J, van den Bosch F, Veale DJ, Wollenhaupt J, Zink A, van der Heijde D (2016) European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 75:499\u2013510","journal-title":"Ann Rheum Dis"},{"key":"4195_CR34","unstructured":"Health K (2016) Kantar Health National Health and Wellness Survey Overview. http:\/\/www.kantarhealth.com\/docs\/uploads\/kantar-health-nhws-overview.pdf . Accessed 19 June, 2018"},{"key":"4195_CR35","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware Jr","year":"1992","unstructured":"Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473\u2013483","journal-title":"Med Care"},{"key":"4195_CR36","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM (1993) The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 4:353\u2013365","journal-title":"Pharmacoeconomics"},{"key":"4195_CR37","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","volume":"16","author":"K Kroenke","year":"2001","unstructured":"Kroenke K, Spitzer RL, Williams JB (2001) The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 16:606\u2013613","journal-title":"J Gen Intern Med"},{"key":"4195_CR38","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/j.1751-7176.2008.07572.x","volume":"10","author":"DE Morisky","year":"2008","unstructured":"Morisky DE, Ang A, Krousel-Wood M, Ward HJ (2008) Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich Conn) 10:348\u2013354","journal-title":"J Clin Hypertens (Greenwich Conn)"},{"key":"4195_CR39","unstructured":"Reilly M (2002) WPAI scoring. http:\/\/www.reillyassociates.net\/WPAI_Scoring.html . Accessed 23 May 2018"},{"key":"4195_CR40","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1136\/jech.53.1.46","volume":"53","author":"C Jenkinson","year":"1999","unstructured":"Jenkinson C, Stewart-Brown S, Petersen S, Paice C (1999) Assessment of the SF-36 version 2 in the United Kingdom. J Epidemiol Community Health 53:46\u201350","journal-title":"J Epidemiol Community Health"},{"key":"4195_CR41","first-page":"680","volume":"35","author":"S Lee","year":"2010","unstructured":"Lee S, Mendelsohn A, Sarnes E (2010) The burden of psoriatic arthritis: a literature review from a global health systems perspective. P T 35:680\u2013689","journal-title":"P T"},{"key":"4195_CR42","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1046\/j.1087-0024.2003.09110.x","volume":"9","author":"J Korte de","year":"2004","unstructured":"de Korte J, Sprangers MA, Mombers FM, Bos JD (2004) Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc 9:140\u2013147","journal-title":"J Investig Dermatol Symp Proc"},{"key":"4195_CR43","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2165\/00128071-200506060-00005","volume":"6","author":"AB Kimball","year":"2005","unstructured":"Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y (2005) The psychosocial burden of psoriasis. Am J Clin Dermatol 6:383\u2013392","journal-title":"Am J Clin Dermatol"},{"key":"4195_CR44","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/j.1468-3083.2010.03600.x","volume":"24","author":"N Meyer","year":"2010","unstructured":"Meyer N, Paul C, Feneron D, Bardoulat I, Thiriet C, Camara C, Sid-Mohand D, Le Pen C, Ortonne JP (2010) Psoriasis: an epidemiological evaluation of disease burden in 590 patients. J Eur Acad Dermatol Venereol 24:1075\u20131082","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4195_CR45","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.semarthrit.2014.05.001","volume":"44","author":"F Matcham","year":"2014","unstructured":"Matcham F, Scott IC, Rayner L, Hotopf M, Kingsley GH, Norton S, Scott DL, Steer S (2014) The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis. Semin Arthritis Rheum 44:123\u2013130","journal-title":"Semin Arthritis Rheum"},{"key":"4195_CR46","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00296-015-3415-x","volume":"36","author":"PC Taylor","year":"2016","unstructured":"Taylor PC, Moore A, Vasilescu R, Alvir J, Tarallo M (2016) A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. Rheumatol Int 36:685\u2013695","journal-title":"Rheumatol Int"},{"key":"4195_CR47","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1111\/jdv.14286","volume":"31","author":"M Augustin","year":"2017","unstructured":"Augustin M, Vietri J, Tian H, Gilloteau I (2017) Incremental burden of cardiovascular comorbidity and psoriatic arthritis among adults with moderate-to-severe psoriasis in five European countries. J Eur Acad Dermatol Venereol 31:1316\u20131323","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4195_CR48","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1136\/annrheumdis-2014-205198","volume":"74","author":"A Kavanaugh","year":"2015","unstructured":"Kavanaugh A, Gladman D, van der Heijde D, Purcaru O, Mease P (2015) Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study. Ann Rheum Dis 74:44\u201351","journal-title":"Ann Rheum Dis"},{"key":"4195_CR49","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s12325-015-0256-7","volume":"32","author":"E Vangeli","year":"2015","unstructured":"Vangeli E, Bakhshi S, Baker A, Fisher A, Bucknor D, Mrowietz U, \u00d6st\u00f6r AJ, Peyrin-Biroulet L, Lacerda AP, Weinman J (2015) A systematic review of factors associated with non-adherence to treatment for immune-mediated inflammatory diseases. Adv Ther 32:983\u20131028","journal-title":"Adv Ther"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-018-4195-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-018-4195-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-018-4195-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T01:38:01Z","timestamp":1775266681000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-018-4195-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,13]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["4195"],"URL":"https:\/\/doi.org\/10.1007\/s00296-018-4195-x","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,13]]},"assertion":[{"value":"10 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"A Gottlieb is a consultant\/advisory board member and is a member of the speakers\u2019 bureaus for AbbVie, Allergan, Beiersdorf Inc., Bristol-Myers Squibb, Celgene Corp, Dermira, Incyte, Janssen, Lilly, Novartis, Reddy Labs, Sun Pharmaceutical Industries, UCB, Valeant, and XBiotech, and has received research\/educational grants from Incyte, Janssen, Lilly, Novartis and UCB. J Gratacos has received consulting fees or other remuneration from AbbVie, Celgene, Janssen-Cilag, MSD, Novartis, Pfizer Inc, and UCB. A Dikranian has received consulting fees or other remuneration from, and has held non-remunerative positions of influence with, AbbVie and Pfizer Inc, is a member of an advisory board for Novartis and Pfizer Inc, and is a member of the speakers\u2019 bureaus for AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Mallinckrodt, Novartis, and Pfizer Inc. A van Tubergen has received grants, research, or clinical trial support from AbbVie, Celgene, Janssen-Cilag, MSD, Novartis, Pfizer Inc, and UCB, is a member of the speakers\u2019 bureaus for Janssen-Cilag, MSD, and Pfizer Inc, and is a consultant or member of an advisory board for Janssen-Cilag, Novartis, and Pfizer Inc. L Fallon, B Emir, L Aikman, and T Smith are shareholders and employees of Pfizer Inc. L Aikman is a shareholder of Pfizer Inc and former employee of Pfizer UK. L Chen is a shareholder and former employee of Pfizer Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights statement"}},{"value":"This study was reviewed and approved by the Pearl Institutional Review Board (IRB). Informed consent was obtained from all individual participants included in the study. The US IRB study number is 16-KAN-127 and the EU study number is 16-KAN-123.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Upon request, and subject to certain criteria, conditions and exceptions (see\n                      \n                      for more information), Pfizer will provide access to individual de-identified participant data from Pfizer-sponsored global interventional clinical studies conducted for medicines, vaccines and medical devices (1) for indications that have been approved in the US and\/or EU or (2) in programs that have been terminated (i.e., development for all indications has been discontinued). Pfizer will also consider requests for the protocol, data dictionary, and statistical analysis plan. Data may be requested from Pfizer trials 24 months after study completion. The de-identified participant data will be made available to researchers whose proposals meet the research criteria and other conditions, and for which an exception does not apply, via a secure portal. To gain access, data requestors must enter into a data access agreement with Pfizer.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data sharing statement"}}]}}